MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

MDT

86.16

+0.34%↑

114.56

-0.5%↓

VEEV

172.73

-1.38%↓

HQY

83.08

+0.23%↑

PHR.US

8.18

-2.5%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.23 1.65

Buy Sell

Overview

Share price change

24h

Current

Min

1.19

Max

1.26

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+87.5% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-43M 131M
Previous open	-0.42
Previous close	1.23

News Sentiment

By Acuity

54%

46%

293 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 kwi 2026, 22:56 UTC

Major News Events

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 kwi 2026, 20:50 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 kwi 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 kwi 2026, 23:23 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 kwi 2026, 23:07 UTC

Earnings

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 kwi 2026, 23:02 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 kwi 2026, 22:39 UTC

Earnings

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 kwi 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 kwi 2026, 22:00 UTC

Major News Events

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 kwi 2026, 22:00 UTC

Major News Events

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 kwi 2026, 21:31 UTC

Major News Events

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 kwi 2026, 20:38 UTC

Earnings

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 kwi 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 kwi 2026, 20:13 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 kwi 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 kwi 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

87.5% upside

12 Months Forecast

Average 2.25 USD 87.5%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

293 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.